1
|
Lion J, Larivière S, Desoutter J, Guillaume N. Characterisation of the novel HLA-B*58:02:04 allele by next-generation sequencing. HLA 2024; 103:e15487. [PMID: 38629729 DOI: 10.1111/tan.15487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 04/02/2024] [Accepted: 04/05/2024] [Indexed: 04/19/2024]
Abstract
HLA-B*58:02:04 differs from HLA-B*58:02:01 by one synonymous nucleotide in codon 215 in exon 4.
Collapse
Affiliation(s)
- Julien Lion
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Sylvie Larivière
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Judith Desoutter
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Nicolas Guillaume
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| |
Collapse
|
2
|
Durand G, Desoutter J, Lorriaux C, Poumaredes G, Joris M, Charbonnier A, Lebon D, Paubelle E, Garcon L, Guillaume N. Platelet transfusions in haploidentical haematopoietic stem cell allograft candidates: Protecting HLA-A and HLA-B antigens through eplet analysis. HLA 2024; 103:e15438. [PMID: 38516935 DOI: 10.1111/tan.15438] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Revised: 01/29/2024] [Accepted: 02/28/2024] [Indexed: 03/23/2024]
Abstract
In patients awaiting an allogeneic haematopoietic stem cell transplantation, platelet transfusion is a risk factor for anti-HLA class I immunization because the resulting donor-specific antibodies complicate the allograft process. The objective of the present study was to determine the feasibility of a novel eplet-based strategy for identifying HLA class I mismatches between potential donors and the recipient when pre-allograft platelet transfusions were required. We included 114 recipient/haploidentical relative pairs. For each pair, we entered HLA-class I typing data into the HLA Eplet Mismatch calculator, defined the list of mismatched eplets (for the recipient versus donor direction) and thus identified the shared HLAs to be avoided. Using this list of HLAs, we defined the theoretical availability of platelet components (PCs) by calculating the virtual panel-reactive antibody (vPRA). We also determined the number of PCs actually available in France by querying the regional transfusion centre's database. The mean ± standard deviation number of highly/moderately exposed eplets to be avoided in platelet transfusions was 5.8 ± 3.3, which led to the prohibition of 38.5 ± 2 HLAs-A and -B. Taking into account the mismatched antigens and the eplet load, the mean ± standard deviation theoretical availability of PCs (according to the vPRA) was respectively 34.49% ± 1.95% for HLA-A and 80% ± 2.3% for HLA-B. A vPRA value below 94.9% for highly or moderately exposed eplets would predict that 10 PCs were actually available nationally. Although epitope protection of HLA molecules is feasible, it significantly restricts the choice of PCs.
Collapse
Affiliation(s)
- Gatien Durand
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Judith Desoutter
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Corinne Lorriaux
- Department of Blood Transfusions, Amiens University Hospital, Amiens, France
| | - Géraldine Poumaredes
- Department of Biology, Etablissement Français du Sang (EFS) Hauts de France, Amiens, France
| | - Magalie Joris
- Department of Clinical Haematology and Cellular Therapy, Amiens University Hospital, Amiens, France
| | - Amandine Charbonnier
- Department of Clinical Haematology and Cellular Therapy, Amiens University Hospital, Amiens, France
| | - Delphine Lebon
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
- Department of Clinical Haematology and Cellular Therapy, Amiens University Hospital, Amiens, France
| | - Etienne Paubelle
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
- Department of Clinical Haematology and Cellular Therapy, Amiens University Hospital, Amiens, France
| | - Loïc Garcon
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Nicolas Guillaume
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
3
|
Lion J, Da Costa C, Guillaume N, Desoutter J. Characterization of the novel HLA-B*07:491 allele by next generation sequencing. HLA 2024; 103:e15342. [PMID: 38180300 DOI: 10.1111/tan.15342] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 12/19/2023] [Accepted: 12/23/2023] [Indexed: 01/06/2024]
Abstract
HLA-B*07:491 differs from HLA-B*07:02:01 by one nucleotide substitution in codon 218 in exon 4.
Collapse
Affiliation(s)
- Julien Lion
- Department of Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Cecilia Da Costa
- Department of Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Nicolas Guillaume
- Department of Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Judith Desoutter
- Department of Histocompatibility, Amiens University Medical Centre, Amiens, France
| |
Collapse
|
4
|
Jacob V, Lambour A, Swinyard B, Zerbib Y, Diouf M, Soudet S, Brochot E, Six I, Maizel J, Slama M, Guillaume N. Annexin-V positive extracellular vesicles level is increased in severe COVID-19 disease. Front Med (Lausanne) 2023; 10:1186122. [PMID: 37332749 PMCID: PMC10272544 DOI: 10.3389/fmed.2023.1186122] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2023] [Accepted: 05/17/2023] [Indexed: 06/20/2023] Open
Abstract
Objectives To evaluate extracellular vesicles levels in a cohort of SARS-CoV-2's patients hospitalized in an intensive care unit with and without COVID-19 associated thromboembolic events. Methods In this study, we aim to assess endothelial and platelet membrane-derived extracellular vesicles levels in a cohort of SARS-CoV-2 patients with and without COVID-19-associated thromboembolic events who were hospitalized in an intensive care unit. Annexin-V positive extracellular vesicles levels were prospectively assessed by flow cytometry in one hundred twenty-three critically ill adults diagnosed with acute respiratory distress syndrome associated with a SARS-CoV-2 infection, ten adults diagnosed for moderate SARS-CoV-2 infection and 25 healthy volunteers. Results On our critically ill patients, thirty-four patients (27.6%) had a thromboembolic event, Fifty-three (43%) died. Endothelial and platelet membrane-derived extracellular vesicles were drastically increased in SARS-CoV-2 patients hospitalized in the ICU compared to healthy volunteers. Moreover a slighty higher small/large ratio for platelets membrane-derived extracellular vesicles in patients was linked to thrombo-embolic events. Conclusion A comparison between total annexin-V positive extracellular vesicles levels in severe and moderate SARS-CoV-2 infection and healthy controls showed a significant increase in patients with severe infection and their sizes could be considered as biomarkers of SARS-CoV-2 associated thrombo-embolic events.
Collapse
Affiliation(s)
- Valentine Jacob
- Department of Human Biology Center, Amiens University Medical Center, Amiens, France
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Alexis Lambour
- Department of Medical Intensive Care Unit, Amiens University Medical Center, Amiens, France
| | - Benjamin Swinyard
- Department of Medical Intensive Care Unit, Amiens University Medical Center, Amiens, France
| | - Yoann Zerbib
- Department of Medical Intensive Care Unit, Amiens University Medical Center, Amiens, France
| | - Momar Diouf
- Department of Statistics, Amiens University Medical Center, Amiens, France
| | - Simon Soudet
- Department of Vascular Medicine, Amiens University Medical Center, Amiens, France
| | - Etienne Brochot
- Department of Human Biology Center, Amiens University Medical Center, Amiens, France
- AGIR Research Unit, Jules Verne University of Picardie, Amiens, France
| | - Isabelle Six
- UR 7517 UPJV, Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications (MP3CV), Jules Verne University of Picardie, Amiens, France
| | - Julien Maizel
- Department of Medical Intensive Care Unit, Amiens University Medical Center, Amiens, France
- UR 7517 UPJV, Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications (MP3CV), Jules Verne University of Picardie, Amiens, France
| | - Michel Slama
- Department of Medical Intensive Care Unit, Amiens University Medical Center, Amiens, France
- UR 7517 UPJV, Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications (MP3CV), Jules Verne University of Picardie, Amiens, France
| | - Nicolas Guillaume
- Department of Human Biology Center, Amiens University Medical Center, Amiens, France
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
5
|
Desoutter J, Lion J, Elsermans V, Top I, Guillaume N. Characterization of the novel HLA-C*05:282Q allele by next generation sequencing. HLA 2023. [PMID: 37226569 DOI: 10.1111/tan.15120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2023] [Revised: 05/14/2023] [Accepted: 05/15/2023] [Indexed: 05/26/2023]
Abstract
HLA-C*05:282Q differs from HLA-C*05:01:01 by one nucleotide substitution in codon -24 in exon 1.
Collapse
Affiliation(s)
- Judith Desoutter
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Julien Lion
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Vincent Elsermans
- Department of Histocompatibility, Lille University Medical Centre, Lille, France
| | - Isabelle Top
- Department of Histocompatibility, Lille University Medical Centre, Lille, France
| | - Nicolas Guillaume
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| |
Collapse
|
6
|
Desoutter J, Lion J, Elsermans V, Top I, Guillaume N. Characterization of the novel HLA-DRB1*14:255 allele by next generation sequencing. HLA 2023. [PMID: 37208991 DOI: 10.1111/tan.15113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Revised: 05/07/2023] [Accepted: 05/09/2023] [Indexed: 05/21/2023]
Abstract
HLA-DRB1*14:255 differs from HLA-DRB1*14:54:01 by one nucleotide substitution in codon 205 in exon 4.
Collapse
Affiliation(s)
- Judith Desoutter
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Julien Lion
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Vincent Elsermans
- Department of Histocompatibility, Lille University Medical Centre, Lille, France
| | - Isabelle Top
- Department of Histocompatibility, Lille University Medical Centre, Lille, France
| | - Nicolas Guillaume
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| |
Collapse
|
7
|
Desoutter J, Lion J, Elsermans V, Top I, Guillaume N. Characterization of the novel HLA-DQB1*06:03:47 allele by next generation sequencing. HLA 2023. [PMID: 37082774 DOI: 10.1111/tan.15073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Revised: 04/11/2023] [Accepted: 04/12/2023] [Indexed: 04/22/2023]
Abstract
HLA-DQB1*06:03:47 differs from HLA-DQB1*06:03:01 by one synonymous nucleotide substitution in codon 158 in exon 3.
Collapse
Affiliation(s)
- Judith Desoutter
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Julien Lion
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| | - Vincent Elsermans
- Department of Histocompatibility, Lille University Medical Centre, Lille, France
| | - Isabelle Top
- Department of Histocompatibility, Lille University Medical Centre, Lille, France
| | - Nicolas Guillaume
- Department Histocompatibility, Amiens University Medical Centre, Amiens, France
| |
Collapse
|
8
|
Lebon D, Dujardin A, Caulier A, Joris M, Charbonnier A, Gruson B, Quint M, Castelain S, François C, Lacassagne MN, Guillaume N, Marolleau JP, Morel P. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease. Leuk Res 2023; 125:107005. [PMID: 36580876 DOI: 10.1016/j.leukres.2022.107005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 11/17/2022] [Accepted: 12/21/2022] [Indexed: 12/25/2022]
Abstract
OBJECTIVES Steroid-refractory graft-versus-host disease (SR-GVHD) is a challenging complication of allogeneic hematopoietic stem cell transplantation, and leads to high morbidity and mortality rates. The orally administered, selective Janus-associated kinase 1/2 inhibitor ruxolitinib gives overall response rates (ORR) of more than 70 % in acute and chronic SR-GVHD. However, several studies have highlighted an elevated risk of cytomegalovirus (CMV) reactivation in patients with ruxolitinib-treated SR-GVHD. METHODS We therefore analyzed risk of CMV and Epstein-Barr virus (EBV) primary infection or reactivation in 57 patients with ruxolitinib-treated GVHD, while taking account of the competing risk (CR) of death prior to the first reactivation. RESULTS Initiation of ruxolitinib treatment was a significant adverse prognostic factor for the CR of first CMV reactivation (hazard ratio (HR)= 1.747, 95 % confidence interval (CI): 1.33-2.92, p < 0.0001) and first EBV reactivation (HR=2.657, 95 % CI: 1.82-3.87, p < 0.0001) during GVHD. In our cohort of ruxolitinib-treated patients, the ORR (48 % and 58 % for acute and chronic GVHD, respectively) and the toxicity profile (haematological adverse events in 29.8 % of the patients) were similar to the literature values. CONCLUSION Given ruxolitinib's efficacy in SR-GVHD, use of this drug should not be limited by the fear of viral reactivation; however, our present results emphasize the importance of monitoring the viral load.
Collapse
Affiliation(s)
- Delphine Lebon
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France; EA 4666, HEMATIM, Université de Picardie Jules Verne, Amiens, France.
| | - Adèle Dujardin
- Unité de Pharmacie Clinique Oncologique, CHU Amiens, Amiens, France
| | - Alexis Caulier
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France; EA 4666, HEMATIM, Université de Picardie Jules Verne, Amiens, France
| | - Magalie Joris
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France
| | - Amandine Charbonnier
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France
| | - Bérengère Gruson
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France
| | - Marine Quint
- Service de Recherche Clinique, CHU Amiens, Amiens, France
| | - Sandrine Castelain
- Laboratoire de Virologie, CHU Amiens, Amiens, France; UR 4294, UCVF, Université de Picardie Jules Verne, Amiens, France
| | - Catherine François
- Laboratoire de Virologie, CHU Amiens, Amiens, France; UR 4294, UCVF, Université de Picardie Jules Verne, Amiens, France
| | | | - Nicolas Guillaume
- EA 4666, HEMATIM, Université de Picardie Jules Verne, Amiens, France; Laboratoire d'Histocompatibilité, CHU Amiens, Amiens, France
| | - Jean-Pierre Marolleau
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France; EA 4666, HEMATIM, Université de Picardie Jules Verne, Amiens, France
| | - Pierre Morel
- Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Amiens, Amiens, France; Département de Biostatistiques, EA 2694-Santé publique, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, France
| |
Collapse
|
9
|
Jacob V, Desoutter J, Guillaume N. Characterization of the novel HLA-DPB1*1359:01 allele by next generation sequencing. HLA 2023; 101:99-100. [PMID: 36086923 DOI: 10.1111/tan.14811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 09/06/2022] [Accepted: 09/07/2022] [Indexed: 12/13/2022]
Abstract
HLA-DPB1*1359:01 differs from HLA-DPB1*03:01:01 by one nucleotide substitution in codon 77 in exon 2.
Collapse
Affiliation(s)
- Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
10
|
Sira L, Zsíros N, Bidiga L, Barna S, Kanyári Z, Nagy EB, Guillaume N, Wild D, Rázsó K, Andó S, Balogh I, Nagy EV, Balogh Z. Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies. Front Endocrinol (Lausanne) 2023; 14:1095815. [PMID: 36923225 PMCID: PMC10008953 DOI: 10.3389/fendo.2023.1095815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Accepted: 02/10/2023] [Indexed: 03/03/2023] Open
Abstract
BACKGROUND Splanchnic vein thrombosis due to co-existing metastatic pancreatic neuroendocrine tumour (pNET) and JAK2V617F mutation is a rare condition. CASE REPORT Here we present a case of a young woman with complete remission of a non-functioning grade 2 pNET with unresectable liver metastases, coexisting with JAK2V617F mutation. Splenectomy and distal pancreatectomy were performed. Neither surgical removal, nor radiofrequency ablation of the liver metastases was possible. Therefore, somatostatin analogue (SSA) and enoxaparine were started. Peptide receptor radionuclide therapy (PRRT) was given in 3 cycles 6-8 weeks apart. Genetic testing revealed no multiple endocrine neoplasia type 1 (MEN-1) gene mutations. After shared decision making with the patient, she gave birth to two healthy children, currently 2 and 4 years old. On pregnancy confirmation, SSA treatment was interrupted and resumed after each delivery. Ten years after the diagnosis of pNET, no tumour is detectable by MRI or somatostatin receptor scintigraphy. PRRT followed by continuous SSA therapy, interrupted only during pregnancies, resulted in complete remission and enabled the patient to complete two successful pregnancies.
Collapse
Affiliation(s)
- Lívia Sira
- Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Noémi Zsíros
- Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - László Bidiga
- Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Sándor Barna
- Department of Nuclear Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Zsolt Kanyári
- Department of Surgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Edit B. Nagy
- Department of Radiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Nicolas Guillaume
- Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland
| | - Damian Wild
- Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland
| | - Katalin Rázsó
- Division of Haematology, Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Szilvia Andó
- Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - István Balogh
- Division of Clinical Genetics, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Endre V. Nagy
- Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- *Correspondence: Endre V. Nagy,
| | - Zoltán Balogh
- Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| |
Collapse
|
11
|
Bazin A, Lorriaux C, Guillaume N, Dupuis M, Coombs J, Poumaredes G, Quelvennec E. L-44 Transfusion plaquettaire, propositions d’amélioration du suivi transfusionnel. Transfus Clin Biol 2022. [DOI: 10.1016/j.tracli.2022.09.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
12
|
Vogel T, Zintler A, Kaiser N, Guillaume N, Lefèvre G, Lederer M, Serra AL, Piros E, Kim T, Schreyer P, Winkler R, Nasiou D, Olivo RR, Ali T, Lehninger D, Arzumanov A, Charpin-Nicolle C, Bourgeois G, Grenouillet L, Cyrille MC, Navarro G, Seidel K, Kämpfe T, Petzold S, Trautmann C, Molina-Luna L, Alff L. Structural and Electrical Response of Emerging Memories Exposed to Heavy Ion Radiation. ACS Nano 2022; 16:14463-14478. [PMID: 36113861 PMCID: PMC9527794 DOI: 10.1021/acsnano.2c04841] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/10/2023]
Abstract
Hafnium oxide- and GeSbTe-based functional layers are promising candidates in material systems for emerging memory technologies. They are also discussed as contenders for radiation-harsh environment applications. Testing the resilience against ion radiation is of high importance to identify materials that are feasible for future applications of emerging memory technologies like oxide-based, ferroelectric, and phase-change random-access memory. Induced changes of the crystalline and microscopic structure have to be considered as they are directly related to the memory states and failure mechanisms of the emerging memory technologies. Therefore, we present heavy ion irradiation-induced effects in emerging memories based on different memory materials, in particular, HfO2-, HfZrO2-, as well as GeSbTe-based thin films. This study reveals that the initial crystallinity, composition, and microstructure of the memory materials have a fundamental influence on their interaction with Au swift heavy ions. With this, we provide a test protocol for irradiation experiments of hafnium oxide- and GeSbTe-based emerging memories, combining structural investigations by X-ray diffraction on a macroscopic, scanning transmission electron microscopy on a microscopic scale, and electrical characterization of real devices. Such fundamental studies can be also of importance for future applications, considering the transition of digital to analog memories with a multitude of resistance states.
Collapse
Affiliation(s)
- Tobias Vogel
- Advanced
Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Alexander Zintler
- Advanced
Electron Microscopy Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Nico Kaiser
- Advanced
Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | | | | | - Maximilian Lederer
- Fraunhofer
IMPS, Center Nanoelectronic Technologies
(CNT), 01109 Dresden, Germany
| | | | - Eszter Piros
- Advanced
Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Taewook Kim
- Advanced
Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Philipp Schreyer
- Advanced
Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Robert Winkler
- Advanced
Electron Microscopy Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Déspina Nasiou
- Advanced
Electron Microscopy Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | | | - Tarek Ali
- Fraunhofer
IMPS, Center Nanoelectronic Technologies
(CNT), 01109 Dresden, Germany
| | - David Lehninger
- Fraunhofer
IMPS, Center Nanoelectronic Technologies
(CNT), 01109 Dresden, Germany
| | - Alexey Arzumanov
- Advanced
Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | | | | | | | | | | | - Konrad Seidel
- Fraunhofer
IMPS, Center Nanoelectronic Technologies
(CNT), 01109 Dresden, Germany
| | - Thomas Kämpfe
- Fraunhofer
IMPS, Center Nanoelectronic Technologies
(CNT), 01109 Dresden, Germany
| | - Stefan Petzold
- Advanced
Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Christina Trautmann
- GSI
Helmholtzzentrum
fuer Schwerionenforschung, 64291 Darmstadt, Germany
- Institute
of Materials Science, TU Darmstadt, 64287 Darmstadt, Germany
| | - Leopoldo Molina-Luna
- Advanced
Electron Microscopy Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Lambert Alff
- Advanced
Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| |
Collapse
|
13
|
Vogel T, Zintler A, Kaiser N, Guillaume N, Lefèvre G, Lederer M, Serra AL, Piros E, Kim T, Schreyer P, Winkler R, Nasiou D, Olivo RR, Ali T, Lehninger D, Arzumanov A, Charpin-Nicolle C, Bourgeois G, Grenouillet L, Cyrille MC, Navarro G, Seidel K, Kämpfe T, Petzold S, Trautmann C, Molina-Luna L, Alff L. Structural and Electrical Response of Emerging Memories Exposed to Heavy Ion Radiation. ACS Nano 2022; 16:14463-14478. [PMID: 36113861 DOI: 10.48328/tudatalib-896] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Hafnium oxide- and GeSbTe-based functional layers are promising candidates in material systems for emerging memory technologies. They are also discussed as contenders for radiation-harsh environment applications. Testing the resilience against ion radiation is of high importance to identify materials that are feasible for future applications of emerging memory technologies like oxide-based, ferroelectric, and phase-change random-access memory. Induced changes of the crystalline and microscopic structure have to be considered as they are directly related to the memory states and failure mechanisms of the emerging memory technologies. Therefore, we present heavy ion irradiation-induced effects in emerging memories based on different memory materials, in particular, HfO2-, HfZrO2-, as well as GeSbTe-based thin films. This study reveals that the initial crystallinity, composition, and microstructure of the memory materials have a fundamental influence on their interaction with Au swift heavy ions. With this, we provide a test protocol for irradiation experiments of hafnium oxide- and GeSbTe-based emerging memories, combining structural investigations by X-ray diffraction on a macroscopic, scanning transmission electron microscopy on a microscopic scale, and electrical characterization of real devices. Such fundamental studies can be also of importance for future applications, considering the transition of digital to analog memories with a multitude of resistance states.
Collapse
Affiliation(s)
- Tobias Vogel
- Advanced Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Alexander Zintler
- Advanced Electron Microscopy Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Nico Kaiser
- Advanced Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | | | | | - Maximilian Lederer
- Fraunhofer IMPS, Center Nanoelectronic Technologies (CNT), 01109 Dresden, Germany
| | | | - Eszter Piros
- Advanced Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Taewook Kim
- Advanced Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Philipp Schreyer
- Advanced Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Robert Winkler
- Advanced Electron Microscopy Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Déspina Nasiou
- Advanced Electron Microscopy Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | | | - Tarek Ali
- Fraunhofer IMPS, Center Nanoelectronic Technologies (CNT), 01109 Dresden, Germany
| | - David Lehninger
- Fraunhofer IMPS, Center Nanoelectronic Technologies (CNT), 01109 Dresden, Germany
| | - Alexey Arzumanov
- Advanced Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | | | | | | | | | | | - Konrad Seidel
- Fraunhofer IMPS, Center Nanoelectronic Technologies (CNT), 01109 Dresden, Germany
| | - Thomas Kämpfe
- Fraunhofer IMPS, Center Nanoelectronic Technologies (CNT), 01109 Dresden, Germany
| | - Stefan Petzold
- Advanced Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Christina Trautmann
- GSI Helmholtzzentrum fuer Schwerionenforschung, 64291 Darmstadt, Germany
- Institute of Materials Science, TU Darmstadt, 64287 Darmstadt, Germany
| | - Leopoldo Molina-Luna
- Advanced Electron Microscopy Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| | - Lambert Alff
- Advanced Thin Film Technology Division, Institute of Materials Science, TU Darmstadt, Alarich-Weiss-Str. 2, 64287 Darmstadt, Germany
| |
Collapse
|
14
|
Jacob V, Desoutter J, Guillaume N. Characterization of the novel
HLA‐C
*03:613
allele by next generation sequencing. HLA 2022; 100:640-641. [DOI: 10.1111/tan.14770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Accepted: 08/12/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Valentine Jacob
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| |
Collapse
|
15
|
Usureau C, Jacob V, Dubois V, Masson D, Jollet I, Desoutter J, Taupin J, Guillaume N. HLA Graph, a free and ready‐to‐use bioinformatics tool to explore anti‐HLA eplets reactivity pattern. HLA 2022; 100:244-253. [DOI: 10.1111/tan.14701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 05/24/2022] [Accepted: 06/05/2022] [Indexed: 11/29/2022]
Affiliation(s)
- Cédric Usureau
- Department of Histocompatibility Amiens University Medical Center Amiens France
- Department of Histocompatibility Hôpital Saint‐Louis Paris France
- SFHI, Société Francophone d'Histocompatibilité et d'Immunogénétique
| | - Valentine Jacob
- Department of Histocompatibility Amiens University Medical Center Amiens France
- SFHI, Société Francophone d'Histocompatibilité et d'Immunogénétique
| | - Valérie Dubois
- SFHI, Société Francophone d'Histocompatibilité et d'Immunogénétique
- Department of Histocompatibility Etablissement Français du Sang, Rhône Alpes Lyon France
| | - Dominique Masson
- SFHI, Société Francophone d'Histocompatibilité et d'Immunogénétique
- Department of Histocompatibility Etablissement Français du Sang, Rhône Alpes Grenoble France
| | - Isabelle Jollet
- SFHI, Société Francophone d'Histocompatibilité et d'Immunogénétique
- Department of Histocompatibility Etablissement Français du Sang, Nouvelle Aquitaine Poitiers France
| | - Judith Desoutter
- Department of Histocompatibility Amiens University Medical Center Amiens France
- SFHI, Société Francophone d'Histocompatibilité et d'Immunogénétique
| | - Jean‐Luc Taupin
- Department of Histocompatibility Hôpital Saint‐Louis Paris France
- SFHI, Société Francophone d'Histocompatibilité et d'Immunogénétique
| | - Nicolas Guillaume
- Department of Histocompatibility Amiens University Medical Center Amiens France
- SFHI, Société Francophone d'Histocompatibilité et d'Immunogénétique
- EA HEMATIM 4666 Jules Verne University of Picardie Amiens France
| |
Collapse
|
16
|
Six I, Guillaume N, Jacob V, Mentaverri R, Kamel S, Boullier A, Slama M. The Endothelium and COVID-19: An Increasingly Clear Link Brief Title: Endotheliopathy in COVID-19. Int J Mol Sci 2022; 23:6196. [PMID: 35682871 PMCID: PMC9181280 DOI: 10.3390/ijms23116196] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 05/25/2022] [Accepted: 05/30/2022] [Indexed: 01/08/2023] Open
Abstract
The endothelium has a fundamental role in the cardiovascular complications of coronavirus disease 2019 (COVID-19). Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) particularly affects endothelial cells. The virus binds to the angiotensin-converting enzyme 2 (ACE-2) receptor (present on type 2 alveolar cells, bronchial epithelial cells, and endothelial cells), and induces a cytokine storm. The cytokines tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 have particular effects on endothelial cells-leading to endothelial dysfunction, endothelial cell death, changes in tight junctions, and vascular hyperpermeability. Under normal conditions, apoptotic endothelial cells are removed into the bloodstream. During COVID-19, however, endothelial cells are detached more rapidly, and do not regenerate as effectively as usual. The loss of the endothelium on the luminal surface abolishes all of the vascular responses mediated by the endothelium and nitric oxide production in particular, which results in greater contractility. Moreover, circulating endothelial cells infected with SARS-CoV-2 act as vectors for viral dissemination by forming clusters that migrate into the circulation and reach distant organs. The cell clusters and the endothelial dysfunction might contribute to the various thromboembolic pathologies observed in COVID-19 by inducing the formation of intravascular microthrombi, as well as by triggering disseminated intravascular coagulation. Here, we review the contributions of endotheliopathy and endothelial-cell-derived extracellular vesicles to the pathogenesis of COVID-19, and discuss therapeutic strategies that target the endothelium in patients with COVID-19.
Collapse
Affiliation(s)
- Isabelle Six
- UR 7517 UPJV, Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications (MP3CV), Picardie Jules Verne University, 80025 Amiens, France; (R.M.); (S.K.); (A.B.); (M.S.)
| | - Nicolas Guillaume
- EA Hematim 4666, Picardie Jules Verne University, 80025 Amiens, France; (N.G.); (V.J.)
- Amiens-Picardie University Medical Center, Human Biology Center, 80054 Amiens, France
| | - Valentine Jacob
- EA Hematim 4666, Picardie Jules Verne University, 80025 Amiens, France; (N.G.); (V.J.)
| | - Romuald Mentaverri
- UR 7517 UPJV, Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications (MP3CV), Picardie Jules Verne University, 80025 Amiens, France; (R.M.); (S.K.); (A.B.); (M.S.)
- Amiens-Picardie University Medical Center, Human Biology Center, 80054 Amiens, France
| | - Said Kamel
- UR 7517 UPJV, Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications (MP3CV), Picardie Jules Verne University, 80025 Amiens, France; (R.M.); (S.K.); (A.B.); (M.S.)
- Amiens-Picardie University Medical Center, Human Biology Center, 80054 Amiens, France
| | - Agnès Boullier
- UR 7517 UPJV, Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications (MP3CV), Picardie Jules Verne University, 80025 Amiens, France; (R.M.); (S.K.); (A.B.); (M.S.)
- Amiens-Picardie University Medical Center, Human Biology Center, 80054 Amiens, France
| | - Michel Slama
- UR 7517 UPJV, Pathophysiological Mechanisms and Consequences of Cardiovascular Calcifications (MP3CV), Picardie Jules Verne University, 80025 Amiens, France; (R.M.); (S.K.); (A.B.); (M.S.)
- Amiens-Picardie University Medical Center, Medical Intensive Care Unit, 80054 Amiens, France
| |
Collapse
|
17
|
Bendjelloul M, Usureau C, Etancelin P, Saidak Z, Lebon D, Garçon L, Marolleau J, Desoutter J, Guillaume N. Utility of assessing
CD3
+
cell chimerism within the first months after allogeneic hematopoietic stem‐cell transplantation for acute myeloid leukemia. HLA 2022; 100:18-23. [PMID: 35064642 PMCID: PMC9303291 DOI: 10.1111/tan.14557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 12/22/2021] [Accepted: 01/19/2022] [Indexed: 11/30/2022]
Affiliation(s)
- Mehdi Bendjelloul
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | - Cédric Usureau
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | | | - Zuzana Saidak
- Laboratory of Molecular Oncobiology, Center of Human Biology, Amiens‐Picardie University Medical Center Amiens France
| | - Delphine Lebon
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
- Department of Clinical Hematology and Cellular Therapy Amiens University Medical Center Amiens France
| | - Loïc Garçon
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| | - Jean‐Pierre Marolleau
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
- Department of Clinical Hematology and Cellular Therapy Amiens University Medical Center Amiens France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM 4666, Jules Verne University of Picardie Amiens France
| |
Collapse
|
18
|
Dakroub F, Touzé A, Sater FA, Fiore T, Morel V, Tinez C, Helle F, François C, Choukroun G, Presne C, Guillaume N, Duverlie G, Castelain S, Akl H, Brochot E. The impact of pre-graft serology on the risk of BKPyV infection post-renal transplantation. Nephrol Dial Transplant 2021; 37:781-788. [PMID: 34586413 DOI: 10.1093/ndt/gfab279] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVES BK polyomavirus associated nephropathy, is a troublesome disease induced by BK polyomavirus (BKPyV) infection in immunocompromised renal graft recipients with no effective available treatment, making immunosuppression reduction the only management option. Thus, pre-graft predictive BKPyV replication markers are needed for high-risk viremia patient identification. METHODS we conducted a retrospective study to assess the correlation between the BKPyV pre-transplant serostatus and post-transplant BKPyV infection incidence. Sera from 329 recipients and 222 matched donors were tested for anti-BKV antibodies against BKPyV serotypes I and IV by a VLPs-based IgG ELISA, and BKPyV DNA load was monitored for at least 1 year post transplantation. RESULTS 80 recipients were viruric and 59 recipients were viremic post transplantation. In the post-transplant period, the probability of developing viremia for serotype I was increasing from 4.3% for the D-/R + group to 12.1% for the D+/R + group and climbing to 37.5% for the D+/R- group (p < 0.05). When calculating the recipient mean titers for serotypes I and IV, we observed a clear difference in the proportions of viremia passing from 50% for mean titers < 400 to 13.5% for titers ≥ 400 (p < 0.001) with also a higher proportion of presumptive nephropathy (50% vs 23.1%, p < 0.05). In univariate analysis this parameter has an odds ratio of 6.41 for the risk of developing post-transplant BKPyV viremia (95% CI: 3.16-13.07; p < 0.0001). CONCLUSIONS Both donor and recipient BKPyV seropositivity determination before transplantation and antibody titer may serve as a predictive tool to manage clinical BKPyV infection by identification of patients at high risk.
Collapse
Affiliation(s)
- Fatima Dakroub
- Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France.,Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences-I, Lebanese University, Hadath, Lebanon
| | - Antoine Touzé
- Infectiologie et santé publique "Biologie des infections à Polyomavirus" team, UMR INRA 1282, University of Tours, Tours, France
| | - Fadi Abdel Sater
- Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences-I, Lebanese University, Hadath, Lebanon
| | - Toni Fiore
- Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France
| | - Virginie Morel
- Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France
| | - Claire Tinez
- Department of Virology, Amiens University Medical Center, Amiens, France.,Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France
| | - François Helle
- Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France
| | - Catherine François
- Department of Virology, Amiens University Medical Center, Amiens, France.,Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France
| | - Gabriel Choukroun
- Department of Nephrology and Transplantation, Amiens University Hospital, Amiens, France
| | - Claire Presne
- Department of Nephrology and Transplantation, Amiens University Hospital, Amiens, France
| | - Nicolas Guillaume
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France; UR4666, Jules Verne University of Picardie, Amiens, France
| | - Gilles Duverlie
- Department of Virology, Amiens University Medical Center, Amiens, France.,Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France
| | - Sandrine Castelain
- Department of Virology, Amiens University Medical Center, Amiens, France.,Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France
| | - Haidar Akl
- Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences-I, Lebanese University, Hadath, Lebanon
| | - Etienne Brochot
- Department of Virology, Amiens University Medical Center, Amiens, France.,Agents infectieux résistance et chimiothérapie Research Unit, UR4294, Jules Verne University of Picardie, France
| |
Collapse
|
19
|
Jacob V, Farce F, Kaveri R, Desoutter J, Guillaume N. Characterization of the novel HLA-DQA1*01:80 allele by next generation sequencing. HLA 2021; 99:68-69. [PMID: 34510809 DOI: 10.1111/tan.14428] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Accepted: 09/07/2021] [Indexed: 11/30/2022]
Abstract
HLA-DQA1*01:80 differs from HLA-DQA1*01:04:01 by one nucleotide substitution in codon -18 in exon 1.
Collapse
Affiliation(s)
- Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Fabienne Farce
- Department of Histocompatibility, EFS Hauts de France-Normandie, Rouen, France
| | - Rangolie Kaveri
- Department of Histocompatibility, EFS Hauts de France-Normandie, Rouen, France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
20
|
Guillaume N, Bélisle MP, Jean M, Dupuis G. Training in tranquil abiding meditation as a treatment for core symptoms and a cognitive remediation program of executive functions in young adults with ADHD: A pilot study. Psychology of Consciousness: Theory, Research, and Practice 2021. [DOI: 10.1037/cns0000294] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
21
|
Jacob V, Farce F, Kaveri R, Desoutter J, Guillaume N. Characterization of the novel HLA-C*04:438 allele by next generation sequencing. HLA 2021; 99:53-54. [PMID: 34498811 DOI: 10.1111/tan.14425] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Accepted: 09/07/2021] [Indexed: 11/29/2022]
Abstract
HLA-C*04:438 differs from HLA-C*04:01:01 by one nucleotide substitution in codon 237 in exon 4.
Collapse
Affiliation(s)
- Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Fabienne Farce
- Department of Histocompatibility, EFS Hauts de France-Normandie, Rouen, France
| | - Rangolie Kaveri
- Department of Histocompatibility, EFS Hauts de France-Normandie, Rouen, France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
22
|
Jacob V, Usureau C, Villemonteix J, Desoutter J, Guillaume N. Characterization of the novel HLA-DRB1*04:326 allele by next generation sequencing. HLA 2021; 98:236-237. [PMID: 34255440 DOI: 10.1111/tan.14369] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Revised: 07/08/2021] [Accepted: 07/09/2021] [Indexed: 11/30/2022]
Abstract
HLA-DRB1*04:326 differs from HLA-DRB1*04:01:01 by one nucleotide substitution in codon 23 in exon 2.
Collapse
Affiliation(s)
- Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Cédric Usureau
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Juliette Villemonteix
- Department of Immunology and Histocompatibility, APHP Hôpital Saint-Louis, Paris, France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
23
|
Jacob V, Usureau C, Fourdrain L, Desoutter J, Guillaume N. Characterization of the novel HLA-C*04:450 allele by next-generation sequencing. HLA 2021; 98:231-232. [PMID: 34231340 DOI: 10.1111/tan.14359] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Accepted: 07/04/2021] [Indexed: 12/01/2022]
Abstract
HLA-C*04:450 differs from HLA-C*04:01:01 by one nucleotide substitution in codon 328 in exon 7.
Collapse
Affiliation(s)
- Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Cédric Usureau
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Ludivine Fourdrain
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
24
|
Jacob V, Dard C, Desoutter J, Guillaume N. Characterization of the novel HLA-C*01:214 allele by sequencing-based typing. HLA 2021; 98:167-168. [PMID: 33993655 DOI: 10.1111/tan.14311] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Revised: 05/11/2021] [Accepted: 05/12/2021] [Indexed: 11/30/2022]
Abstract
HLA-C*01:214 differs from HLA-C*01:02:01:01 by one nucleotide substitution in codon -10 in exon 1.
Collapse
Affiliation(s)
- Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Céline Dard
- Department of Histocompatibility, EFS Auvergne Rhône Alpes, La Tronche, France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
25
|
Dubois V, Amokrane K, Crocchiolo R, Fort M, Guillaume N, Kennel A, Michiels S, Ralazamahaleo M, Rouzaire PO, Yakoub-Agha I, Faucher C. [Definition and standardization of histocompatibility requests depending on patient course and donor type: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society of Histocompatibility and Immunogenetics (SFHI)]. Bull Cancer 2021; 108:S45-S52. [PMID: 33966883 DOI: 10.1016/j.bulcan.2021.01.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 01/27/2021] [Accepted: 01/27/2021] [Indexed: 10/21/2022]
Abstract
Standardization of histocompatibility tests for allogeneic hematopoietic cell transplants, harmonization of information transmitted to clinicians are part of quality improvement and optimization of human and economic resources. New HLA typing technologies provide high-resolution information within a reasonable time frame. Knowledge of high-resolution HLA typing for the patient and their relatives is essential for a better interpretation of compatibilities. HLA-DPB1 typing must be considered in transplant field regardless of the donor type. The benefits of using search and match programs are considerable. It saves time and reduces additional typing costs by providing rapid information about the likelihood to identify a matched unrelated donor. A backup therapy considering alternative cell sources or treatment can therefore be quickly implemented. The importance of knowledge and consideration of patient immunization for donor choice was explored in previous workshops of the SFGM-TC (2018 and 2019). The published recommendations remain applicable. The routine follow-up protocol and in case of desensitization will be detailed here. This harmonization must be accompanied by the standardization of information to be returned to the clinician regarding the donor finding possibilities for the patient. This will guarantee a similar quality level in every center.
Collapse
Affiliation(s)
- Valérie Dubois
- Établissement Français du Sang, laboratoire Histocompatibilité, 69150 Décines, France.
| | - Kahina Amokrane
- Hôpital Saint Louis, laboratoire d'Immunologie Histocompatibilité, 75010 Paris, France
| | - Roberto Crocchiolo
- Servizio di Immunoematologia e Medicina Trasfusionale, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italie
| | - Marylise Fort
- CHU de Toulouse, laboratoire d'Histocompatibilité, Hôpital de RANGUEIL, 31059 Toulouse, France
| | | | - Anne Kennel
- Établissement Français du Sang, laboratoire Histocompatibilité, 42000 Saint-Étienne, France
| | - Sandra Michiels
- Institut Jules Bordet, Département d'Hématologie, Université Libre de Bruxelles, 1000 Bruxelles, Belgique
| | - Mamy Ralazamahaleo
- CHU de Bordeaux, laboratoire d'Immunologie-Immunogénétique, 33076 Bordeaux
| | - Paul-Olivier Rouzaire
- CHU de Clermont-Ferrand, Service d'Histocompatibilité et d'Immunogénétique, Université Clermont Auvergne, EA 7453 CHELTER, 63003 Clermont-Ferrand
| | | | - Catherine Faucher
- Direction prélèvements et greffes de CSH, Direction médicale et scientifique, Agence de la biomédecine, 93212 St-Denis, La Plaine
| |
Collapse
|
26
|
Usureau C, Lefèvre E, Top I, Nikolski M, Varlet P, Choukroun G, Desoutter J, Guillaume N. Antibodies against HLA cross-reactivity groups: From single antigen bead assay to immunoinformatics interpretation of epitopes. Mol Immunol 2021; 133:154-162. [PMID: 33667985 DOI: 10.1016/j.molimm.2021.02.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 01/26/2021] [Accepted: 02/23/2021] [Indexed: 11/30/2022]
Abstract
Identification of anti-human leukocyte antigen (HLA) antibodies (Abs) is based on Luminex™ technology. We used bioinformatics to (i) study the correlations of mean fluorescence intensities (MFIs) for all the possible allele pairs, and (ii) determine the degree of epitope homology between HLA antigens. Using MFI data on anti-HLA Abs from 6000 Luminex™ assays, we provide an updated overview of class I and II HLA antigen cross-reactivity in which each node corresponded to an allele and each link corresponded to a strong correlation between two alleles (Spearman's ρ > 0.8). We compared these correlations with the serological groups and the results of an epitope analysis. The strongest correlations concerned allele-specific Abs directed against the same antigen. For the HLA-A locus, the highest values of Spearman's ρ reflected broad specificity. For the HLA-B locus, graphs defined the HLA-Bw4 public epitope, and correlations between HLA-A and -B alleles were only present for beads with the same Bw4 public epitope. For the HLA-C locus, we identified two groups that differed with regard to their KIR ligand subclassification. Lastly, the HLA-DRB1 subgroups were part of a network. In the epitope analysis, Spearman's ρ was related to the number of matched epitopes within pairs of alleles. The combination of Spearman's ρ with simple, undirected graphing constitutes an effective tool for understanding routinely encountered cross-reactivity profiles. Based on this model, we have implemented an online data visualization tool available at http://cusureau.pythonanywhere.com/.
Collapse
Affiliation(s)
- Cédric Usureau
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France; EA 4666 Hematim, Jules Verne University of Picardie, Amiens, France; French Speaking Society of Histocompatibility and Immunogenetic (SFHI), France
| | - Edgar Lefèvre
- Bordeaux Bioinformatics Center, CNRS, IBGC CNRS UMR 5095, Bordeaux University, Bordeaux, France
| | - Isabelle Top
- French Speaking Society of Histocompatibility and Immunogenetic (SFHI), France; Department of Immunology and Histocompatibility, Lille University Hospital, Lille, France
| | - Macha Nikolski
- Bordeaux Bioinformatics Center, CNRS, IBGC CNRS UMR 5095, Bordeaux University, Bordeaux, France
| | - Pauline Varlet
- French Speaking Society of Histocompatibility and Immunogenetic (SFHI), France; Department of Immunology and Histocompatibility, Lille University Hospital, Lille, France
| | - Gabriel Choukroun
- Department of Nephrology and Transplantation, Amiens University Hospital, Amiens, France
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France; EA 4666 Hematim, Jules Verne University of Picardie, Amiens, France; French Speaking Society of Histocompatibility and Immunogenetic (SFHI), France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France; EA 4666 Hematim, Jules Verne University of Picardie, Amiens, France; French Speaking Society of Histocompatibility and Immunogenetic (SFHI), France.
| |
Collapse
|
27
|
Desoutter J, Usureau C, Jacob V, Lebon D, Caulier A, Da Costa C, Charbonnier A, Joris M, Marolleau JP, Guillaume N. A one-step assay for sorted CD3 + cell purity and chimerism after hematopoietic stem cell transplantation. HLA 2020; 97:183-187. [PMID: 33314632 DOI: 10.1111/tan.14168] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 10/06/2020] [Accepted: 12/11/2020] [Indexed: 11/30/2022]
Abstract
A hematopoietic chimerism assay is the laboratory test for monitoring engraftment and quantifying the proportions of donor and recipient cells after hematopoietic stem cell transplantation recipients. Flow cytometry is the reference method for determining the purity of CD3+ cells on the chimerism of selected CD3+ cells. In the present study, we developed a single-step procedure that combines the CD3+ purity assay (using the PCR-based Non-T Genomic Detection Kit from Accumol, Calgary, Canada) and the qPCR chimerism monitoring assay (the QTRACE qPCR assay from Jeta Molecular, Utrecht, the Netherlands). First, for the CD3+ purity assay, we used a PCR-friendly protocol by changing the composition of the ready-to-use reaction tubes (buffer and taq polymerase) and obtained a satisfactory calibration plot (R2 = 0.8924) with a DNA reference scale of 2 ng/μl. Next, 29 samples (before and after CD3 positive selection) were analyzed, the mean cell purity was, respectively, 19.6% ± 6.45 and 98.9% ± 1.07 in the flow cytometry assay; 26.8% ± 7.63 and 98.5% ± 1.79 in the PCR-based non-T genomic detection assay. Our results showed that the CD3+ purity assay using a qPCR kit is a robust alternative to the flow cytometry assay and is associated with time savings when combined with a qPCR chimerism assay.
Collapse
Affiliation(s)
- Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Cédric Usureau
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Valentine Jacob
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Delphine Lebon
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France.,Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Alexis Caulier
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France.,Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Cécilia Da Costa
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| | - Amandine Charbonnier
- Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Magalie Joris
- Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Jean-Pierre Marolleau
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France.,Department of Clinical Hematology and Cellular Therapy, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.,EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
28
|
Lanore A, Brisset M, Maisonobe T, Guillaume N. Neurolymphomatose associée à un lymphome T non-Hodgkin révélée par une polyneuropathie axonale. Rev Neurol (Paris) 2020. [DOI: 10.1016/j.neurol.2020.01.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
29
|
Guillaume N, Jean M, Marcaurelle R, Dupuis G. Mindfulness meditation versus training in tranquil abiding: Theoretical comparison and relevance for developing concentration. Psychology of Consciousness: Theory, Research, and Practice 2020. [DOI: 10.1037/cns0000222] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
30
|
Usureau C, Jacob V, Clichet V, Presne C, Desoutter J, Poulain C, Choukroun G, Guillaume N. Flow cytometry crossmatching to investigate kidney-biopsy-proven, antibody-mediated rejection in patients who develop de novo donor-specific antibodies. Transpl Immunol 2020; 61:101303. [PMID: 32387224 DOI: 10.1016/j.trim.2020.101303] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 04/26/2020] [Accepted: 04/27/2020] [Indexed: 11/19/2022]
Abstract
INTRODUCTION The appearance of de novo donor-specific anti-human leukocyte antigen antibodies (dnDSAs) after kidney transplantation is independently associated with poor long-term allograft outcomes. The objective of the present study was to evaluate the predictive value of a flow cytometry crossmatching (FC-XM) assay after the appearance of dnDSAs related to antibody-mediated allograft rejection (ABMR) after kidney transplantation. MATERIALS AND METHODS A total of 89 recipients with dnDSAs after transplantation were included. The crossmatching results were compared with the dnDSA profile (the mean fluorescence intensity (MFI), the complement-binding activity, and the IgG subclass profile) and the biopsy's morphological features. RESULTS Of the 89 patients, 59 (66%) were positive in an FC-XM assay, 17 (19%) had complement-binding DSAs, 55 (62%) were positive for IgG1 and/or IgG3 in a solid phase assay, and 45 (51%) had morphological biopsy features linked to ABMR. CONCLUSION An FC-XM assay was unable to discriminate between cases with or without ABMR on biopsy findings; it had a low positive predictive value (<70%) and a low negative positive predictive value (<42.9%), taking into account the sensitivity of our assay (limit of detection: DSAs with an MFI >3000). In this context, the height of the MFI of the dnDSAs might be enough for a high positive predictive value for ABMR and additional testing for complement binding activity can remain optional.
Collapse
Affiliation(s)
- Cédric Usureau
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France; EA Hematim, Jules Verne University of Picardie, Amiens, France
| | - Valentine Jacob
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France; EA Hematim, Jules Verne University of Picardie, Amiens, France
| | - Valentin Clichet
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France; EA Hematim, Jules Verne University of Picardie, Amiens, France
| | - Claire Presne
- Department of Nephrology and Transplantation, Amiens University Hospital, Amiens, France
| | - Judith Desoutter
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France; EA Hematim, Jules Verne University of Picardie, Amiens, France
| | - Coralie Poulain
- Department of Nephrology and Transplantation, Amiens University Hospital, Amiens, France
| | - Gabriel Choukroun
- Department of Nephrology and Transplantation, Amiens University Hospital, Amiens, France
| | - Nicolas Guillaume
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France; EA Hematim, Jules Verne University of Picardie, Amiens, France.
| |
Collapse
|
31
|
Desoutter J, Jacob V, Guillaume N. HLA-B*15:47:01 allele with undefined serological equivalent considered as B Blank. Int J Immunogenet 2019; 47:65-66. [PMID: 31599086 DOI: 10.1111/iji.12457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 09/02/2019] [Accepted: 09/18/2019] [Indexed: 11/26/2022]
Abstract
We report a discordance between complement-dependent cytotoxicity and next-generation sequencing molecular typing revealing HLA-B*15:47:01 allele with undefined serological equivalent confirmed by high-level immunization against the B15 serotype. Due to the high-level immunization against HLA-B15 and B70 antigens, we considered the HLA-B*15:47:01 allele to be B Blank and not as B15 or B70 serological specificity.
Collapse
Affiliation(s)
- Judith Desoutter
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France.,EA 4666 HEMATIM, Jules Verne University of Picardie, Amiens, France
| | - Valentine Jacob
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France.,EA 4666 HEMATIM, Jules Verne University of Picardie, Amiens, France
| | - Nicolas Guillaume
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France.,EA 4666 HEMATIM, Jules Verne University of Picardie, Amiens, France
| |
Collapse
|
32
|
Kwadwo A, Guillaume N, Wild D, Christ E. Erratum to: Molecular imaging for neuroendeocrine tumours. Swiss Med Wkly 2019; 149:w20076. [DOI: 10.4414/smw.2019.20076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
33
|
Lefeuvre C, Brisset M, Robert-Yves C, Durand MC, Guillaume N, Pascal L, Malfatti E. Spectre phénotypique des myopathies avec mutation de l’Anoctamin-5. Rev Neurol (Paris) 2019. [DOI: 10.1016/j.neurol.2019.01.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
34
|
Guillaume N. Improved flow cytometry crossmatching in kidney transplantation. HLA 2018; 92:375-383. [DOI: 10.1111/tan.13403] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2018] [Revised: 09/11/2018] [Accepted: 09/28/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Nicolas Guillaume
- Department of Histocompatibility Amiens University Medical Center Amiens France
- EA HEMATIM Jules Verne University of Picardie Amiens France
| |
Collapse
|
35
|
Fechtenbaum M, Desoutter J, Delvallez G, Brochot E, Guillaume N, Goëb V. MICA and NKG2D variants as risk factors in spondyloarthritis: a case-control study. Genes Immun 2018; 20:599-605. [PMID: 30177859 PMCID: PMC6768283 DOI: 10.1038/s41435-018-0044-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Revised: 07/22/2018] [Accepted: 07/24/2018] [Indexed: 01/27/2023]
Abstract
The major histocompatibility complex class I polypeptide-related sequence A (MICA) glycoprotein mediates the activation of the natural killer group 2D receptor (NKG2D) expressed on NK and CD8+ T cells. A methionine or valine at position 129 in exon 3 results in strong (MICA129 met) or weak (MICA129 val) binding to NKG2D. The MICA A5.1 allele causes a premature stop codon. Various NKG2D polymorphisms are associated with low (NKC3 C/C and NKC4 C/C) or high (NKC3 G/G and NKC4 T/T) levels of NK cell cytotoxic activity. In 162 patients with spondyloarthritis (115 with ankylosing spondyloarthritis, 46 with psoriatic arthritis and 1 with reactive arthritis) compared to 124 healthy controls, MICA-129 with methionine allele was more frequent in patients with spondyloarthritis (odds ratio (OR) (95% confidence interval) = 4.84 (2.75‒8.67)), whereas MICA-129 val/val, MICA A5.1 and NKC3 C/C variants were less frequent (OR = 0.20 (0.11‒0.37), 0.15 (0.06‒0.36) and 0.24 (0.13‒0.44), respectively). After adjustment for HLA-B*27 status, only NKC3 C/C remained linked to spondyloarthritis (adjusted OR = 0.14 (0.06‒0.33)). Homozygosity for MICA A5.1 is linked to ankylosing spondyloarthritis, and NKC3 C/C and MICA-129 val/val to psoriatic arthritis. MICA and NKC3 polymorphisms (related to a low NK cell cytotoxic activity) constituted a genetic association with spondyloarthritis.
Collapse
Affiliation(s)
- Marie Fechtenbaum
- Department of Rheumatology, Amiens University Medical Center, Amiens, France. .,Jules Verne University of Picardie, EA HEMATIM, Amiens, France.
| | - Judith Desoutter
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Gauthier Delvallez
- Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France
| | - Etienne Brochot
- Department of Virology, Amiens University Medical Center, Amiens, France
| | - Nicolas Guillaume
- Jules Verne University of Picardie, EA HEMATIM, Amiens, France. .,Department of Hematology and Histocompatibility, Amiens University Medical Center, Amiens, France.
| | - Vincent Goëb
- Department of Rheumatology, Amiens University Medical Center, Amiens, France.,Jules Verne University of Picardie, EA HEMATIM, Amiens, France
| |
Collapse
|
36
|
Apithy MJ, Desoutter J, Guillaume N. Comparison of two peripheral mononuclear cell isolation protocols for flow cytometry crossmatching. HLA 2017; 91:124-126. [PMID: 29240309 DOI: 10.1111/tan.13192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2017] [Revised: 11/17/2017] [Accepted: 12/10/2017] [Indexed: 11/30/2022]
Abstract
In clinical organ transplantation, flow cytometry crossmatching can be performed on total blood with a hemolysis step or after a preliminary mononuclear cell separation step using a standard Ficoll-Hypaque protocol. Here, we compared the Ficoll-Hypaque step with a faster technique for isolating mononuclear cells (the SepMate tube), using the same samples (collected and stored at room temperature for 0, 24, 48 or 72 hours). We found that the SepMate separation protocol is easily applied to flow cytometry crossmatching (with or without pronase treatment), provided that the samples have been stored at room temperature for 48 hours or less. Conversely, the Ficoll-Hypaque protocol should be used if the samples have been stored for more than 48 hours at room temperature.
Collapse
Affiliation(s)
- M-J Apithy
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France
| | - J Desoutter
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France
| | - N Guillaume
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France
| |
Collapse
|
37
|
Roussel B, Guillaume N, Lefrère JJ, Betsou F. Long-term stability of coagulation variables: Protein S as a biomarker for preanalytical storage-related variations in human plasma. Thromb Haemost 2017. [DOI: 10.1160/th08-10-0679] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
38
|
Bodeau S, Quinton M, Sauzay C, Bennis Y, Etienne I, Romezin J, Meynier J, Guillaume N, Hazzan M, Galmiche A, Choukroun G. Le polymorphisme VEGF 936 C>T est-il associé à un effet protecteur vis-à-vis du risque de carcinome à cellules rénales post-transplantation ? Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
39
|
Bennis Y, Bodeau S, Lutun A, Gourmel A, Solas C, Quaranta S, Guillaume N, Chouaki T, Lemaire‐Hurtel A, Masmoudi K. Severe neurological disorders and refractory aspergillosis in an adolescent treated by vincristine and voriconazole. J Clin Pharm Ther 2017; 43:265-268. [DOI: 10.1111/jcpt.12603] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Accepted: 07/03/2017] [Indexed: 11/27/2022]
Affiliation(s)
- Y. Bennis
- Pharmacology and Toxicology Laboratory Department of Clinical Pharmacology Amiens University Medical Center INSERM U1088 UPJV Amiens France
| | - S. Bodeau
- Pharmacology and Toxicology Laboratory Department of Clinical Pharmacology Amiens University Medical Center INSERM U1088 UPJV Amiens France
| | - A. Lutun
- Department of Pediatric Oncology Amiens University Medical Center Amiens France
| | - A. Gourmel
- Department of Pediatric Oncology Amiens University Medical Center Amiens France
| | - C. Solas
- Pharmacokinetics and Toxicology Laboratory La Timone University Medical Center INSERM U‐911 CRO2 Aix‐Marseille University Marseille France
| | - S. Quaranta
- Pharmacokinetics and Toxicology Laboratory La Timone University Medical Center INSERM U‐911 CRO2 Aix‐Marseille University Marseille France
| | - N. Guillaume
- Department of Hematology Amiens University Medical Centre Amiens France
| | - T. Chouaki
- Mycology Laboratory Amiens University Medical Centre Amiens France
| | - A.‐S. Lemaire‐Hurtel
- Pharmacology and Toxicology Laboratory Department of Clinical Pharmacology Amiens University Medical Center INSERM U1088 UPJV Amiens France
| | - K. Masmoudi
- Pharmacovigilance Regional Center Department of Clinical Pharmacology Amiens University Medical Center Amiens France
| |
Collapse
|
40
|
Apithy MJ, Desoutter J, Gicquel A, Guiheneuf E, Westeel PF, Lesage A, Piot V, Choukroun G, Guillaume N. Pronase treatment improves flow cytometry crossmatching results. HLA 2017; 90:157-164. [DOI: 10.1111/tan.13073] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 06/03/2017] [Accepted: 06/07/2017] [Indexed: 11/27/2022]
Affiliation(s)
- M.-J. Apithy
- Department of Histocompatibility; Amiens University Medical Center; Amiens France
- Department of Hematology; Amiens University Medical Center; Amiens France
| | - J. Desoutter
- Department of Histocompatibility; Amiens University Medical Center; Amiens France
- Department of Hematology; Amiens University Medical Center; Amiens France
| | - A. Gicquel
- Department of Histocompatibility; Amiens University Medical Center; Amiens France
- Department of Hematology; Amiens University Medical Center; Amiens France
| | - E. Guiheneuf
- Department of Hematology; Amiens University Medical Center; Amiens France
| | - P.-F. Westeel
- Department of Nephrology and Transplantation; Amiens University Medical Center; Amiens France
| | - A. Lesage
- Department of Histocompatibility; Amiens University Medical Center; Amiens France
| | - V. Piot
- Department of Histocompatibility; Amiens University Medical Center; Amiens France
| | - G. Choukroun
- Department of Nephrology and Transplantation; Amiens University Medical Center; Amiens France
| | - N. Guillaume
- Department of Histocompatibility; Amiens University Medical Center; Amiens France
- Department of Hematology; Amiens University Medical Center; Amiens France
- EA466; University of Picardie; Amiens France
| |
Collapse
|
41
|
Desoutter J, Apithy MJ, Guillaume N. Unexpected Positive Prospective Crossmatches in Organ Transplant. EXP CLIN TRANSPLANT 2017; 15:253-259. [PMID: 28447927 DOI: 10.6002/ect.2016.0346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Preformed donor-specific antibodies against human leukocyte antigen can induce antibody-mediated rejection after organ transplant. Hence, future transplant recipients undergo pretransplant screening for preformed antibodies (ie, virtual crossmatch). Subsequently, prospective (analytic) crossmatching is performed using conventional, complement-dependent cytotoxicity assays and/or flow cytometry-based methods. The present article reviews factors that must be considered when unexpected, positive, prospective crossmatches are observed. First, the prozone effect caused by the interference of complement or immunoglobulin M must be abrogated by treating the serum with moderate heat, dilution, hypotonic dialysis, EDTA, or dithiothreitol. Second, the physician must check for the presence of potentially interfering autoantibodies (in a context of autoimmune disease or human immunodeficiency virus infection) or therapeutic antibodies (such as rituximab and antithymocyte globulin). In conclusion, knowledge of each assay's technical characteristics will enable the physician to reliably interpret any discrepancies. The reasons for an unexpected, positive, prospective crossmatch must be elucidated before transplant to ensure efficient organ allocation and optimize patient outcomes.
Collapse
Affiliation(s)
- Judith Desoutter
- From the Department of Histocompatibility, Amiens University Medical Center, Amiens, France
| | | | | |
Collapse
|
42
|
Brochot E, Desoutter J, Presne C, De Araujo I, Flahaut G, Castelain S, Westeel PF, Choukroun G, Guillaume N. The association between killer-cell immunoglobulin-like receptor (KIR) and KIR ligand genotypes and the likelihood of BK virus replication after kidney transplantation. Transpl Int 2016; 29:1168-1175. [PMID: 27516136 DOI: 10.1111/tri.12820] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 02/25/2016] [Accepted: 07/27/2016] [Indexed: 12/01/2022]
Abstract
BK virus is a common opportunistic post-transplantation viral infection. Although some risk factors have been studied in this context, the contribution of NK cells has not been assessed in detail. In a group of kidney transplant recipients, we studied the association between (i) the likelihood of BK virus replication during the two-year period after kidney transplantation and (ii) the genotypes of the killer cell immunoglobulin-like receptor (KIR) repertoire and their human leukocyte antigen (HLA) ligands. Other clinical factors (such as defective organ recovery and immunosuppressive treatment) were also assessed. BK virus replication was observed in 43 of the 103 recipients (41%). Patients with BK virus replication in the plasma were more likely to display defective organ recovery in the first seven days post-transplantation. BK virus replication was not associated with Missing KIR ligands. However, BK virus replication was more frequent in patients with responsive NK cells (i.e. when a ligand for activating KIRs was not homozygous in the recipient and present in the donor). Our results suggest that defective organ recovery and the recipient's activating KIR repertoire may be related (depending on HLA ligands present in the couple recipient / donor) to the reactivation of BK virus replication after kidney transplantation.
Collapse
Affiliation(s)
- Etienne Brochot
- Virology Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France.,Department of Virology, Amiens University Medical Center, Amiens, France
| | - Judith Desoutter
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France.,EA 4666, Jules Verne University of Picardie, Amiens, France
| | - Claire Presne
- Department of Nephrology Dialysis Transplantation, Amiens University Medical Center, Amiens, France.,INSERM 1088, Jules Verne University of Picardie, Amiens, France
| | - Isabelle De Araujo
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France.,EA 4666, Jules Verne University of Picardie, Amiens, France
| | - Gauthier Flahaut
- Department of Nephrology Dialysis Transplantation, Amiens University Medical Center, Amiens, France.,INSERM 1088, Jules Verne University of Picardie, Amiens, France
| | - Sandrine Castelain
- Virology Research Unit, EA 4294, Jules Verne University of Picardie, Amiens, France.,Department of Virology, Amiens University Medical Center, Amiens, France
| | - Pierre-François Westeel
- Department of Nephrology Dialysis Transplantation, Amiens University Medical Center, Amiens, France.,INSERM 1088, Jules Verne University of Picardie, Amiens, France
| | - Gabriel Choukroun
- Department of Nephrology Dialysis Transplantation, Amiens University Medical Center, Amiens, France.,INSERM 1088, Jules Verne University of Picardie, Amiens, France
| | - Nicolas Guillaume
- Department of Histocompatibility, Amiens University Medical Center, Amiens, France. .,EA 4666, Jules Verne University of Picardie, Amiens, France.
| |
Collapse
|
43
|
Guillaume N, Loiseau P, Gagne K, Teissserenc HM, Cayuela JM, Henry G, Robin M, Peffault de Latour R, Gluckman E, Socié G, Retiere C, Dulphy N, Toubert A. Natural killer cell licensing after double cord blood transplantation is driven by the self-HLA class I molecules from the dominant cord blood. Haematologica 2016; 101:e209-12. [PMID: 26819052 DOI: 10.3324/haematol.2015.138883] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Affiliation(s)
- Nicolas Guillaume
- Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Amiens, France Laboratoire d'Hématologie et d' Histocompatibilité, EA 4666 «Lymphocyte Normal - Pathologique et Cancers», Centre Hospitalier Universitaire, Amiens, France
| | - Pascale Loiseau
- Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Amiens, France Assistance Publique-Hopitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France Inserm, UMRS-1160, Institut Universitaire d'Hématologie, Paris
| | - Katia Gagne
- Etablissement Français du Sang (EFS), Laboratoire d'Histocompatibilité, Nantes, France EFS, Laboratoire de Recherche EA4271, Nantes, France LabEx Transplantex, University of Strasbourg, Paris, France
| | - Hélène Moins Teissserenc
- Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Amiens, France Assistance Publique-Hopitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France Inserm, UMRS-1160, Institut Universitaire d'Hématologie, Paris Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, EA3518, Paris, France
| | - Jean-Michel Cayuela
- Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, EA3518, Paris, France AP-HP, Laboratoire d'Hématologie, Hôpital Saint-Louis, Paris, France
| | - Guylaine Henry
- Assistance Publique-Hopitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France
| | - Marie Robin
- AP-HP, Hématologie -Transplantation; Hôpital Saint Louis, Paris, France
| | | | | | - Gérard Socié
- Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Amiens, France AP-HP, Hématologie -Transplantation; Hôpital Saint Louis, Paris, France
| | - Christelle Retiere
- EFS, Laboratoire de Recherche EA4271, Nantes, France LabEx Transplantex, University of Strasbourg, Paris, France
| | - Nicolas Dulphy
- Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Amiens, France Assistance Publique-Hopitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France Inserm, UMRS-1160, Institut Universitaire d'Hématologie, Paris LabEx Transplantex, University of Strasbourg, Paris, France
| | - Antoine Toubert
- Université Paris-Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Amiens, France Assistance Publique-Hopitaux de Paris (AP-HP), Hôpital Saint-Louis, Laboratoire d'Immunologie et Histocompatibilité, Paris, France Inserm, UMRS-1160, Institut Universitaire d'Hématologie, Paris LabEx Transplantex, University of Strasbourg, Paris, France
| |
Collapse
|
44
|
Petitprez V, Royer B, Desoutter J, Guiheneuf E, Rigolle A, Marolleau JP, Kamel S, Guillaume N. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. Int J Lab Hematol 2014; 37:29-35. [PMID: 24661393 DOI: 10.1111/ijlh.12216] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2013] [Accepted: 02/20/2014] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Osteolytic bone destruction is a major clinical problem in multiple myeloma patients. Osteoclasts can differentiate in vitro from bone marrow-resident monocyte progenitors, such as common monocyte progenitors, as well as circulating monocytes. Various types of monocytes, including osteoclast precursors, appear to circulate systemically. METHODS We investigated the possibility of demonstrating, by in vitro differentiation and flow cytometry, a circulating osteoclast precursor population in multiple myeloma (MM) patients by studying the distribution of CD14(+/++) CD11b(+) CD51/61(+) and CD14(+/++) CD16(+/-) populations. RESULTS Under short-term in vitro osteoclastic differentiation conditions, almost all CD14 monocytes acquired CD51/61 and CD16 expression. Flow cytometry studies failed to demonstrate a statistically significant increase in circulating CD14(+/++) CD11b(+) CD51/61(+) populations in 20 MM patients with osteolytic lesions. However, the minor circulating CD14(+/++) CD16(+) fraction was significantly increased in MM patients compared with healthy volunteers (109.3 ± 63.1/mm(3) vs. 65.3 ± 34.9/mm(3) ; P = 0.005), but with no correlation with markers of tumour burden. The CD14(+/++) CD16(+) to CD14(+/++) CD16(-) ratio was higher in MM patients. CONCLUSION The circulating CD14(+/++) CD11b(+) CD51/61(+) fraction was not correlated with bone lesions in MM patients. However, CD14(+/++) CD16(+) monocytes may be a candidate marker. A larger study must be conducted to confirm these promising results for the diagnosis and follow-up of MM patients.
Collapse
Affiliation(s)
- V Petitprez
- Haematology and Histocompatibility Laboratory, Amiens University Hospital, Amiens, France
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Guillaume N, Mazouz H, Piot V, Presne C, Westeel PF. Correlation between Luminex donor-specific crossmatches and levels of donor-specific antibodies in pretransplantation screening. ACTA ACUST UNITED AC 2013; 82:16-20. [PMID: 23621167 DOI: 10.1111/tan.12128] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2012] [Revised: 03/12/2013] [Accepted: 04/01/2013] [Indexed: 11/30/2022]
Abstract
Before kidney transplantation, recipients are routinely screened for preformed antibodies and prospective crossmatches. In this study, we compared prospective Luminex donor-specific crossmatches (LumXm) with the levels of identified, donor-specific antibodies (DSAs). LumXm was performed for 108 patient sera, 84 of which were positive for preformed antibodies and 24 of which were negative. Although LumXm can detect class I DSAs (anti-A and anti-B) with a mean fluorescence intensity (MFI) as low as 2300, the assay has a 'grey zone' for MFIs up to 4000 with a sensitivity of 54% and a specificity of 100%. LumXm can detect a class II DSA (anti-DRB1) with an MFI as low as 1300 and a sensitivity of 93% and a specificity of 99%. However, these correlations were obtained with two precautions: autocrossmatching and single-antigen bead assay with denaturing buffer were performed in discordant cases. Moreover, LumXm failed to detect anti-Cw and anti-DP in the 10 cases studied. LumXm, therefore, displays certain discrepancies with respect to single-bead assays--especially for antibodies with a low MFI. Unfortunately, LumXm has a low sensitivity for anti-A and anti-B class I antibodies.
Collapse
Affiliation(s)
- N Guillaume
- Laboratoire d'Hématologie et d'Histocompatibilité, Centre Hospitalier Universitaire, Amiens, France.
| | | | | | | | | |
Collapse
|
46
|
Guillaume N, Marolleau JP. Is immune escape via human leukocyte antigen expression clinically relevant in chronic lymphocytic leukemia? Focus on the controversies. Leuk Res 2013; 37:473-7. [DOI: 10.1016/j.leukres.2012.12.021] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2012] [Revised: 12/24/2012] [Accepted: 12/29/2012] [Indexed: 11/26/2022]
|
47
|
Guillaume N, Desoutter J, Chandesris O, Merlusca L, Henry I, Georgin-Lavialle S, Barete S, Hirsch I, Bouredji D, Royer B, Gruson B, Lok C, Sevestre H, Mentaverri R, Brazier M, Meynier J, Hermine O, Marolleau JP, Kamel S, Damaj G. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013. [PMID: 23200108 DOI: 10.1016/j.amjmed.2012.07.018] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVES Mastocytosis is a heterogeneous group of clonal mast cell disorders in which bone manifestations are frequently seen, but poorly understood. In this study, we analyzed correlation of clinical findings in mastocytosis patients with bone mineral density and bone turnover markers. METHODS Serum levels of bone turnover markers were measured in mastocytosis patients and healthy volunteers. Bone disease was evaluated using radiographic imaging, and measurement of bone mineral density. RESULTS Of 45 adult mastocytosis patients, bone abnormalities were detected in 34 (75%). Bone lesions were documented on radiographic imaging in 16 patients (36%), and bone mineral density in 24 patients (53%), of which 9 patients (20%) had osteoporosis and 15 (33%) had osteopenia. Serum levels of bone turnover markers that evaluate bone resorption (C-telopeptide, deoxypyridinoline), bone formation (bone-specific alkaline phosphatase), and bone remodeling (osteoprotegerin) were significantly higher in the patient population than in the control population (n=28). Levels of C-telopeptide and osteoprotegerin were higher in patients with advanced systemic mastocytosis than in patients with cutaneous or indolent systemic mastocytosis. Moreover, C-telopeptide and osteoprotegerin levels were significantly correlated with those of serum tryptase, a diagnostic marker of mastocytosis. CONCLUSION The observed bone turnover markers variations indicate a complex process of bone turnover in mastocytosis-related bone manifestations. The highly significant correlation between serum tryptase and serum bone turnover markers levels, and the positive correlation of levels of bone turnover markers with advanced disease, support the existence of a link between bone remodeling and mast cell burden.
Collapse
|
48
|
Wen H, Zhao Z, Fefelova N, Allen C, Guillaume N, Xiao D, Huang C, Zang W, Gwathmey J, Xie L. Docosahexaenoic Acid Reduces the Incidence of Early Afterdepolarizations Caused by Oxidative Stress in Rabbit Ventricular Myocytes. Heart Rhythm 2012. [DOI: 10.1016/j.hrthm.2012.09.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Guillaume N, Vaida I, Capiod JC, Claisse JF. Acute promyelocytic leukemia with atypical cytologic features. Acta Cytol 2009; 53:723-4. [PMID: 20014570 DOI: 10.1159/000325423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
50
|
Guillaume N, Gouilleux-Gruart V, Claisse JF, Troussard X, Lepelley P, Damaj G, Royer B, Garidi R, Lefrere JJ. Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2009; 48:1556-60. [PMID: 17701587 DOI: 10.1080/10428190701457931] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
ZAP-70 and CD38 expression can identify B-cell chronic lymphocytic leukemia with an inferior clinical outcome. Many groups have investigated the meaning of the expression of these two proteins and the correlation with the bad prognosis in B-CLL. But nobody has investigated the relation between the multidrug resistance mediated by Pgp overexpression (MDR1) and ZAP-70/CD38 coexpression. Forty-one untreated and stage A patients, either ZAP-70(+)CD38(+) or ZAP-70(-)CD38(-), were tested to determine the MDR1 status. MDR1 was observed in 41% of CLL ZAP-70(+)CD38(+) and in 37% of CLL ZAP-70(-)CD38(-). The difference was not significant (p = 0.745). Patients with ZAP-70 and CD38 positive CLL can not be candidates for MDR1 antagonists.
Collapse
MESH Headings
- ADP-ribosyl Cyclase 1/metabolism
- ATP Binding Cassette Transporter, Subfamily B
- ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism
- Aged
- Aged, 80 and over
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Female
- Gene Expression Regulation, Leukemic
- Humans
- Immunoblotting
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Male
- Membrane Glycoproteins/metabolism
- Middle Aged
- Prognosis
- Up-Regulation
- ZAP-70 Protein-Tyrosine Kinase/metabolism
Collapse
Affiliation(s)
- Nicolas Guillaume
- Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Amiens, France.
| | | | | | | | | | | | | | | | | |
Collapse
|